CVRx develops and commercializes Barostim, an FDA-approved neuromodulation device that treats heart failure with reduced ejection fraction by delivering electrical pulses to baroreceptors in the carotid artery, activating the autonomic nervous system to counteract the neurohormonal imbalance underlying disease progression. The Barostim system comprises an implantable pulse generator with multi-year battery life, a stimulation lead, surgical accessories, and a wireless programmer for therapy adjustment. CVRx sells the device primarily to hospitals serving heart failure specialists, cardiologists, and cardiothoracic surgeons; hospitals bill third-party payers including Medicare and commercial insurers for implantation procedures. The company operates a direct sales organization in the U.S. and Germany, with distributors in other European markets, and generates revenue from device sales complemented by reimbursement from Medicare, commercial insurers, and international payers at rates that vary by procedure type and geography.